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Abstract
Background: Myocardial fibrosis is a key process in diabetic cardiomyopathy. However, their underlying
mechanisms have not been elucidated, leading to a lack of therapy. The glucagon-like peptide-1 (GLP-1) enhancer,
sitagliptin, reduces hyperglycemia but may also trigger direct effects on the heart.
Methods: Goto-Kakizaki (GK) rats developed type-II diabetes and received sitagliptin, an anti-hyperglycemic drug
(metformin) or vehicle (n=10, each). After cardiac structure and function assessment, plasma and left ventricles were
isolated for biochemical studies. Cultured cardiomyocytes and fibroblasts were used for in vitro assays.
Results: Untreated GK rats exhibited hyperglycemia, hyperlipidemia, plasma GLP-1 decrease, and cardiac cell-
death, hypertrophy, fibrosis and prolonged deceleration time. Moreover, cardiac pro-apoptotic/necrotic, hypertrophic
and fibrotic factors were up-regulated. Importantly, both sitagliptin and metformin lessened all these parameters. In
cultured cardiomyocytes and cardiac fibroblasts, high-concentration of palmitate or glucose induced cell-death,
hypertrophy and fibrosis. Interestingly, GLP-1 and its insulinotropic-inactive metabolite, GLP-1(9-36), alleviated these
responses. In addition, despite a specific GLP-1 receptor was only detected in cardiomyocytes, GLP-1 isoforms
attenuated the pro-fibrotic expression in cardiomyocytes and fibroblasts. In addition, GLP-1 receptor signalling may
be linked to PPARδ activation, and metformin may also exhibit anti-apoptotic/necrotic and anti-fibrotic direct effects in
cardiac cells.
Conclusions: Sitagliptin, via GLP-1 stabilization, promoted cardioprotection in type-II diabetic hearts primarily by
limiting hyperglycemia e hyperlipidemia. However, GLP-1 and GLP-1(9-36) promoted survival and anti-hypertrophic/
fibrotic effects on cultured cardiac cells, suggesting cell-autonomous cardioprotective actions.
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Introduction
The global prevalence of type-II diabetes mellitus (T2DM)
has increased in such a way that has achieved epidemic
proportions [1]. Experimental and clinical studies have shown
an association between T2DM and cardiomyopathy, being
defined by functional and structural changes at the level of
myocardium, independent of any vascular or cardiac diseases.
Diabetic cardiomyopathy (DCM) is characterized by myocardial
apoptosis, hypertrophy and subsequent fibrosis, as well as
cardiac dysfunction [2]. The intervention to prevent the
development of fibrosis has been proposed for the treatment of
DCM [3, 4]. An excess of plasma free fatty-acid (FFA) and
glucose triggers pro-fibrotic factors and extracellular matrix
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(ECM) deposition from fibroblasts and myocytes [2,3].
However, the molecular underlying mechanisms of these
responses are poorly known, leading to a lack of treatment. In
this regard, metformin is the only anti-diabetic conclusively
probed to avoid cardiac complications in diabetes.
Unfortunately, this insulin-sensitizer can produce unwanted
side effects [1]. Dipeptidyl peptidase-IV (DPP-IV) inhibitors, as
sitagliptin, are a new class of anti-diabetics that prevent the
degradation of insulinotropic incretins, without producing
hypoglycemia [5]. The most active incretin is glucagon-like
peptide-1-(7-36), usually termed GLP-1. GLP-1 is released
from intestinal L-cells to the circulation in response to ingested
nutrient. GLP-1 regulates blood glucose mainly by enhancing
pancreatic insulin secretion, and confers cardioprotection after
myocardial infarction, congestive heart failure and ischemia
[6,7]. However, the expression of DPP-IV and GLP-1 receptors
(GLP-1R) has been also described in different tissues including
liver, vessel and heart, suggesting extra-pancreatic actions
[6-9]. Via RISK (cAMPPKAPI3KAkt) pathway GLP-1R induce
transcription factor activation [10,11]. In this sense, peroxisome
proliferator-activated receptors (PPAR) are FFA-binding
nuclear receptors that act as transcription factors to regulate
cardiac metabolic and inflammatory genes [12]. In particular,
PPARδ may control pro-fibrotic genes to prevent cardiac
fibrosis and heart failure [13]. However, due to the plasma
DPP-IV activity, GLP-1 is degraded within minutes to the
insulinotropic-inactive GLP-1(9-36) [5]. The aim of this study
was to investigate whether sitagliptin could induce
cardioprotection for T2DM hearts by GLP-1/PPARδ direct
actions on cardiac cells.
Methods
Ethics Statement
These investigations adhered to the Guide for the Care and
Use of Laboratory Animals (NIH Publication No. 85–23, revised
1996) and the Ethics Committee of the IIS-Fundación Jiménez
Díaz Hospital granted approval for these experiments (ref.
2012/5).
Animal Model
A polygenic non-obese non-hypertensive model of T2DM
was used for the study. Male Goto-Kakizaki (GK) rats were
purchased from Taconic, Denmark and were kept on an
artificial 12-hour light-dark cycle (7 a.m.-7 p.m.) at 25°C. GK
exhibit similar metabolic, hormonal and vascular disorders that
the human T2DM, offering a convenient model for the study of
T2DM per se, without the confounding effects of obesity or
hypertension [14]. Once GK became diabetic (at 16th week),
some were treated with sitagliptin [Merck Sharp & Dohme
(Spain), 10 mg/Kg/day] or metformin clorhidrato [Acofarma
(Spain), 200 mg/Kg/day]. Both drugs were dissolved in water
and daily administrated (10 a.m.) by a gavage. Vehicle-treated
GK and wistar were also examined. N=10, each group. Body
weight, diet consumption and systolic blood pressure
(measured by tail-cuff method) were weekly evaluated. After 10
weeks of treatment, plasma (collected from cava vein) and
hearts were isolated (3-7 p.m.) under isoflurane (1.5% in O2)
anaesthesia. Plasma lipid profile, glucose, hepatic enzymes
and renal parameters were enzymatically measured in the
clinical department of the Hospital. Hearts were rinsed, dried
and weighted. After atria excision, a ventricular slice was
included in p-formaldehyde and paraffin for histology. Then, left
ventricles were frozen in liquid-N2 for biochemical assays.
Glucose tolerance test
Glucose tolerance was evaluated as published elsewhere
[15]. Blood samples were collected (from tail vein) at the day
before sacrifice after overnight fasting (N=10, each group).
Then, rats received the corresponding dose of vehicle or
sitagliptin and plasma was immediately obtained, after which
glucose solution (0.5 g/kg) was administrated by i.p. Fifteen
and sixty minutes after glucose loading, plasma was obtained
again. Plasma glucose and insulin were measured by ELISA
kits (Mercodia AB; Sweden). Plasma GLP-1 was determined by
modification of Orskov method [16]. Samples [collected in glass
tubes with DPP-IV inhibitors (Vacutainer P700, BD; USA)] were
mixed with 0.5M EDTA, 10,000 UIC/ml aprotinin and absolute
ethanol for 1h at 4°C, and centrifuged (3,000 rpm, 15 min at
4°C). Supernatants were frozen in liquid-N2, lyophilized and
dissolved in 0.2M glycin-0.5% human serum albumin-500U/ml
aprotinin solution (pH 8,8). Then, 100 µl were used for GLP-1
quantification by ELISA (Epitope Diagnostic Inc.; USA).
Cardiac structure and function measurement
Cardiac echocardiography was performed under 1.5%
isoflurane-O2 anaesthesia in all rats before (not shown) and
after the treatments. Both M-mode and two-dimensional (2D)
echocardiograms were obtained using a 12 MHz ultra-band
sector transducer (En Visor-C-HD, Philips). Images were
obtained from the left and right parasternal window in a supine
decubitus position. The following parameters were measured
and calculated from M-mode tracing: left ventricular (LV) end-
diastolic diameter (LVDD), LV end-systolic diameter (LVSD)
and ejection fraction (EF; by Teichzol method). Wall thickness
of four segments [anterior, inter-ventricular-septum (IVS),
lateral, and posterior (LVPW) walls] was evaluated on short
axis 2D images. LV mass index (LVMI) was calculated
according to Devereux method using LVPW, IVS and LVDD
parameters, and normalized to body weight as previously
described [17]. For histological quantification of the LVPW and
IVS thicknesses, serial paraffin sections (4 µm) of half-height
sliced myocardium were fixed on slides and stained with
Haematoxylin/Eosin (H/E). LVPW and IVS thicknesses were
evaluated as mean of 4-5 measurements in the same heart
region of all rats by using Metamorph software. A
representative photograph taken with an optical microscopy,
and the score for each rat are shown. Cell size of LVPW
cardiomyocytes was quantified in 50 transversally oriented
H/E-stained cells of twenty randomly fields by average of the
cross-sectional areas (at nucleus level), using Metamorph.
Cardiac fibrosis and cell-death examination
Masson trichrome was used to detect extra-cellular matrix
(ECM) deposition by sequent addition of Bouin’s, Weigert’s and
Biebrich solutions (Bio-Optica, Milan, Italy) on paraffin sections
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(4 µm) of all myocardia. Interstitial, perivascular and
replacement fibrosis were quantified together on five fields of
each myocardium using the Metamorph software. Photographs
with a scale bar were taken at 40x magnification under optical
microscopy. Apoptosis was detected by a TUNEL-based
apoptosis detection kit, following manufacture’s instructions
(ApopTag®, Invitrogen). The percentage of TUNEL-positive
nuclei relative to total nuclei was determined in a blinded
manner by counting 200-300 cells on ten randomly chosen
fields per coverslip for each myocardium. In vitro, cells were
cultured in chamber slides (Nunc; Naperville, IL), stimulated,
fixed with methanol:acetone (1:1) and nuclear-stained with
DAPI. Condensed, pyknotic and/or fragmented nuclei of death
cells were identified by confocal microscopy and were counted
by using Metamorph. Necrosis was evaluated in the hearts by
loss of cytoskeleton vinculin in paraffin-fixed slides by
incubations with an anti-vinculin antibody followed by a
biotinylated secondary antibody (Cell Signalling, USA), as
previously described [32]. Representative photographs were
taken under confocal microscopy. In cultured cardiomyocytes
necrosis was measured by the release of the cytolytic glucose
6-phosphate dehydrogenase (G6PD) from damage and dying
cells into the media, using the Vybranto Cytotoxicity Assay Kit
(Invitrogen).
Cultured cardiomyocytes and fibroblasts
A derived cardiac muscle cell line, designated HL-1, from the
AT-1 mouse atrial cardiomyocyte tumour lineage was used for
in vitro assays. These cells (kindly given by Dr. Zalba,
Pamplona, Spain) [18] retain differentiated cardiac
morphological, biochemical, and electrophysiological
properties, and exhibit a pattern of gene expression similar to
that of adult myocytes [19]. HL-1 were grown in gelatin/
fibronectin-coated plates with Claycomb medium (Sigma-
Aldrich; USA) supplemented with 10% (vol/vol) heat-inactivated
foetal calf serum (FBS), 10 μM norepinephrine, 100 IE/ml Na+-
penicillin, 2 mM L-glutamine and 5 mM D-glucose (Sigma-
Aldrich; USA). Cardiac fibroblasts from adult male wistar rats
were obtained by differential centrifugation of cardiac cells
released after retrograde Langendorff perfusion with a Ca++-
free tyrode solution and enzymatic digestion with 250 UI of
collagenase type-II, as previously described [20]. The
fibroblasts were resuspended in DMEM medium supplemented
with 10% FBS, 10 mM L-glutamine, 100 U/ml penicillin/
streptomycin, 10 mM L-pyruvate and 2 mM HEPES. Cells were
used at 2-3 passages. Also, a cell line of interstitial fibroblasts
(TFB; kindly given by Dr. Nielson, USA) [21] derived from
murine kidney was growth in RPMI-1640 medium
supplemented with 5% FBS, 2% penicillin/streptomycin and 5
mM glucose (Sigma). All cells were switched to serum-free
quiescent medium overnight before stimulation. The
hyperlipidemic or hyperglycemic conditions were mimicked by
incubation (6-24h) with high concentration of a common
saturated FFA (HF; sodium palmitate 16:0, 0.25 mM) or
glucose (HG; D-glucose 33 mM) (Sigma), respectively.
Palmitate was previously conjugated with BSA in a 3:1 molar
ratio as published elsewhere [22]. In control cells, BSA was
added as described but in the absence of palmitate. Some cells
were pre-treated with sitagliptin (1h, 0.5 μM) since its peak
plasma concentration after a single oral dose of 100 mg (10 mg
in rats) is about 0.5-0.6 μM, which is reported to produce nearly
complete inhibition of DPP-IV [23]. GLP-1(7-36) (1 nM),
GLP-1(9-36) (0.3 nM) (Sigma) or metformin clorhidrato (5 mM)
were added 30 min before stimulation. A PPARδ-agonist
[GW0742 (10 μM), Sta. Cruz Biotech, USA] or antagonist
[G5797 (10 μM), Sigma] was added 24h before stimulation.
Western Blot (WB)
A piece (50 mg) of homogenized ventricle (by Bullet Blender,
Cultek) or cell extract were dissolved in protein lysis buffer (50
mM Tris-HCl pH 7.5, 1 mM EDTA, 2% SDS + 1/250
mammalian protease inhibitors), and equal amounts (20-30 μg)
of protein extracts were separated on polyacrylamide gels,
transferred to membranes and probed with specific primary
antibodies [anti-fibronectin (Millipore, Darmstadt, Germany), -
collagen type-I precursor (Millipore), -PPARδ (Aviva System
Biology; USA), -caspase-3, -AMPK or -APMK-P (Cell
Signalling)]. Anti-GAPDH (Sigma) was used as loading control.
Then, secondary antibodies (GE Healthcare) were used for
chemo-luminescence development. A representative gel of at
least three independent experiments with the semi-
quantification score (n-fold) is shown in the figures. For
quantification of soluble fibronectin, cultured cells were starved
in 1% FBS (to prevent proteases activity) before stimulation,
after which, cell media were collected, centrifuged (12,000 rpm
at 4°C) to remove cell debris, and loaded (20 μg) on
polyacrylamide gels. Since cells do not secrete GAPDH,
Ponceau staining was used as a loading control.
Immunofluorescence (IF)
Fibronectin was localized in HL-1. After stimulation, cells
were washed and fixed with 4% p-formaldehyde. Anti-
fibronectin (Millipore) was added overnight at 4°C and
developed with anti-rabbit FITC-linked goat antibody (Sigma).
4′,6-diamidino-2-phenylindole (DAPI, Sigma) was used for
nuclear labeling. Fibronectin staining was quantified by
Metamorph on ten randomly fields in at least three independent
experiments. Cardiomyocyte size was quantified as previously
described [24] as surface area from ten randomly chosen fields
of actin-stained cells [with an anti-F-actin phalloidin antibody
(Sigma)], in at least three independent experiments.
Representative photographs with a bar scale were taken at 40x
magnification under confocal microscopy.
Quantitative-PCR (QPCR)
Total RNA was extracted from homogenized ventricle (50
mg) or cultured cardiomyocytes by dissolving in Trizol reagent
(Invitrogen). Equal amounts of RNA were reverse-transcripted
to obtain the cDNA for multiplex QPCR. Mixture of QPCR was
prepared as it follows: 33 ng of cDNA or 1:100 dilution of pre-
amplified cDNA, 0.25 μl of gene expression assays [0.125 μl
TGFß1 (Rn00572010_m1), CTGF (Rn00573960_m1), BNP
(Rn00580641_m1) or α-SMA (Rn00570060_g1) Fam-
fluorophore + 0.125 μl housekeeping gene eukaryotic
ribosomic 18s vic-fluorophore (4310893E)], 5 μl premix buffer
(polymerase and salts) and RNAase free water (Applied
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Biosystems). Amplification conditions were: 2’ at 50°C, 10’’ at
95°C and 40 cycles of 15’’ at 95°C and 1’ at 60°C. For GLP-1R
detection, cDNA (100 ng) was pre-amplified (10’ at 95°C and
10 cycles of 15’’ at 95°C and 4’ at 60°C) with TaqMan PreAmp
Master Mix (Applied Biosystems) before singleplex QPCR. All
samples were prepared in triplicate to obtain their threshold
cycle (Ct). If deviation for each triplicate were higher than 0.3
cycles, Ct was not considered. The relative expression for each
gene was achieved following the model R=2-ΔΔCt. We show the
quantification (-fold gene vs. 18s) of at least two QPCRs of all
rats or three independent cultured cardiomyocytes
experiments.
Statistical analysis
Data are expressed as mean±standard deviation. Multiple
comparisons were performed by non-parametric Kruskal-Wallis
test followed by a Mann-Whitney test. A two-tailed p<0.05 was
considered significant.
Results
Characterization of the GK associated T2DM model
After 10 weeks of treatments, the patho/physiological
parameters of the experimental model are shown in Figure 1a.
GK rats showed elevated circulating levels of glucose, lipid
profile [cholesterol (Ch), triglycerides (TG), non-HDL Ch, non-
esterified fatty acids (NEFA) and high-density lipoproteins
(HDL)], and proteinuria, compared to control hearts. GK also
exhibited a modest but significant increase in heart-to-femur
length ratio (HW/FL). Interestingly, both sitagliptin and
metformin attenuated hyperglycemia, hyperlipidemia and
proteinuria, and restored HW/FL (Figure 1a). Plasma ions (Na+,
Cl- and K+), markers of severe renal (urea, blood urea nitrogen,
creatin and albumin) and liver (ASAT and ALAT) injury (not
shown), and systolic blood pressure remained within the
normal ranges in all groups of rats.
Sitagliptin attenuated the ventricular thickness, cell
hypertrophy and cell-death of GK hearts
By Echo-Doppler (Figure 1b), GK showed a significant
increase of LV posterior wall (LVPW) thickness and LV mass
index (LVMI), resulting in a decreased LV diastolic (LVDD) and
systolic (LVSD) diameters. Deceleration time was also
prolonged in GK, suggesting diastolic dysfunction, and the
ejection fraction (EF) was elevated. Sitagliptin treatment
significantly reduced the LVPW, LVMI and deceleration time
(Figure 1b). Metformin exhibited a decreased deceleration time
and a non-significant trend to restore LVPW and LVMI. Cardiac
wall thickness was also analysed in sitagliptin-treated hearts
stained with H/E (Figure 1c). We confirmed the increase of
LVPW in the GK myocardium and its diminution by sitagliptin.
Moreover, we measured the cardiomyocyte diameters in this
LVPW area. GK showed a significant increase of the cross-
sectional area (1.41±0.04-fold vs. 1.0±0.03 wistar, p<0.05),
which was reduced after sitagliptin (1.14±0.09-fold vs. wistar,
p<0.05).
In addition, we also observed an increase of death cells in
the GK myocardium (142.5±5.5%-fold vs. wistar, p<0.05). GK
exhibited apoptotic myocytes and fibroblasts, and also vascular
cells (mainly endothelial cells) (Figure 2a). In this regard, GK
up-regulated pro-apoptotic caspase-3 (Figure 2b).
Furthermore, necrotic cells were identified by a loss of the
cytoskeleton protein vinculin. In this sense, GK hearts showed
a decrease of vinculin (Figure 2a). Interestingly, sitagliptin and
metformin reduced both apoptotic (125.5±3.0%-fold and
98.3±5.2%-fold vs. GK, respectively. p<0.05) and necrotic cells
in the GK myocardia (Figure 2b), which was confirmed by
restoration of caspase-3 and vinculin (Figure 2a).
Sitagliptin reduced myocardial fibrosis and pro-fibrotic
factors
Left ventricular myocardium in the wistar rats showed a
normal architecture with regular interstitial space (Figure 2c). In
contrast, abnormal myocardial architecture (cardiomyocyte
disarray and increased interstitial space) was observed in the
GK group. Masson trichrome staining detected a deposition of
ECM within the interstitial and mainly peri-vascular areas
(green-blue staining, Figure 2c). Interestingly, in both sitagliptin
and metformin-treated rats, ECM accumulation was markedly
reduced. Thus, we next focused on the fibrotic component by
examining the expression of key cardiac ECM proteins. Pro-
type-I collagen and fibronectin were found elevated in GK rats
(Figure 2d, left). However, only fibronectin was reverted with
both sitagliptin and metformin. Furthermore, the mRNA
expression of pro-fibrotic inducers, such as transforming
growth factor-ß1 (TGFß1) and its cofactor, connective tissue
growth factor (CTGF), were also up-regulated in the GK
myocardium and restored with both treatments (Figure 2d,
right).
Sitagliptin increased GLP-1 secretion in fasting and
glucose-overload states in GK rats
Previous data had indicated that sitagliptin could increase
plasma GLP-1 in a glucose-dependent manner [24,25]. By a
glucose tolerance test, we observed in the fasting state (0 min)
that GLP-1 levels were diminished in GK rats and moderately
reverted after sitagliptin (Figure 3a), which may correlate with
the increase of insulin (Figure 3b) and ameliorated glucose
(Figure 3c) in these rats. Then, mainly after 60 min of glucose
loading, GK showed decreased levels of GLP-1 (Figure 3a)
and a delayed insulin response (Figure 3b), which could be
responsible for the increasing concentration of plasma glucose
(Figure 3c). However, also after 60 min, sitagliptin-treated rats
kept higher levels of GLP-1 (Figure 3a) and insulin (Figure 3b),
which may achieve for the slight but significant glycemic
reduction (Figure 3c).
Expression of cardiac GLP-1 receptors
The existence of GLP-1 receptor (GLP-1R) has been
described in the heart, specifically in cardiomyocytes but not in
fibroblasts [8]. We indeed detected GLP-1R mRNA expression
in the rat hearts (Figure 4a, left). GK exhibited higher GLP-1R
expression than wistar, and sitagliptin did not modify this value.
As expected, in contrast to cardiac fibroblast and TFB (not
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Figure 1.  Sitagliptin and metformin reduced HW/FL, hyperglycemia, hyperlipidemia and proteinuria in GK rats.  (a) Physical
and plasmatic parameters were evaluated in the rats (n=10, each group). Representative photographs of rats and hearts for each
group are also shown. BW, body weight; HW, heart weight, FL, femur length; Ch, cholesterol, TG, triglycerides; LDL and HDL, low-
and high-density lipoproteins; NEFA, non-esterified fatty acid; S.B.P., systolic blood pressure. (b) Sitagliptin mitigated cardiac
hypertrophy in GK rats. The LV posterior wall (LVPW) and inter-ventricular septum (IVS) thicknesses, LV diastolic (LVDD) and LV
systolic (LVSD) diameters, LV mass index (LVMI), ejection fraction (EF) and the deceleration time were achieved in the rats
myocardia (n=10, each g roup). Representative Echo-Doppler images for each group of rats are also shown (top). (c) Hematoxilin/
Eosin staining of rat hearts with the corresponding semi-quantitative score of LVPW and IVS thicknesses. *p<0.05 and **p<0.01 vs.
wistar. †p<0.05 and ††p<0.01 vs. GK rats.
doi: 10.1371/journal.pone.0078330.g001
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Figure 2.  Sitagliptin and metformin reduced T2DM-associated cell-death and fibrosis in the heart.  (a) By TUNEL, detection
of apoptotic cells in the myocardium (see arrows) and heart vessel (see arrowheads). At the bottom, a typical striated-like pattern
immunostaining of vinculin (see arrows). (b) Caspase-3 expression in the hearts. (c) Masson staining for wistar, GK and GK-treated
hearts showing ECM accumulation (green-blue staining) (n=10, each group). (d) ECM protein [pro-type-I collagen and fibronectin
(FN)] levels, and pro-fibrotic mRNA expression (TGFß1 and CTGF) (n=10, each group). *p<0.05 and **p<0.01 vs. wistar. †p<0.05
and ††p<0.01 vs. GK rats.
doi: 10.1371/journal.pone.0078330.g002
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shown), we detected GLP-1R mRNA expression in HL-1
cardiomyocytes, and this was not significantly changed after 6h
of HF, HG or GLP-1 incubation (Figure 4a, right). The presence
of GLP-1R in the heart and cardiomyocytes suggested a direct
role of GLP-1 in the DCM.
GLP-1 regulated HF- and/or HG-induced pro-fibrosis,
hypertrophy and cell-death in cardiomyocytes
An excess of FFA and glucose are main components of the
hyperlipidemic and hyperglycemic milieu in DCM [2,22]. We
stimulated HL-1 cardiomyocytes with both compounds and
focused on the pro-fibrotic response. After 24h, high-
concentration of FFA (HF) or glucose (HG) triggered fibronectin
expression (Figure 4b, by WB and IF) and secretion to the
cultured media (Figure 4c). When both HF and HG were added
Figure 3.  Sitagliptin improved glucose intolerance in
GK.  rats. Plasma (a) GLP-1, (b) insulin and (c) glucose were
evaluated in the rats before (fasting) and 15-min/60-min after
glucose loading (n=10, each group). The G-black arrow
indicates glucose-overload. *p<0.05 and **p<0.01 vs. wistar.
†p<0.05 and ††p<0.01 vs. GK rats. §p<0.05 and §§p<0.01 vs.
fasting state.
doi: 10.1371/journal.pone.0078330.g003
together, fibronectin was not significantly further stimulated (not
shown). In concordance, the mRNA expression of pro-fibrotic
cytokines, such as TGFß1 and CTGF, were also up-regulated
after 6h of HF or HG (Figure 4d). Then, since sitagliptin
increased GLP-1 plasma levels (Figure 3a) and reduced
myocardial fibrosis in GK rats (Figure 2a), we assayed whether
GLP-1 may modulate the pro-fibrotic response to HF and HG in
cardiomyocytes. GLP-1 pre-treatment (1 nM) attenuated
fibronectin expression (Figure 4b, by WB and IF) and secretion
(Figure 4c) in HF or HG-induced cells. GLP-1 alone did not
significantly alter fibronectin content in control cells (Figure 4b-
c). Moreover, GLP-1 decreased pro-fibrotic TGFß1 transcripts
after HG, and CTGF after HF or HG incubation (Figure 4d).
In addition, we studied whether HF and HG could induce pro-
hypertrophic and lethal influences on cardiomyocytes and
whether GLP-1 may alleviate these effects. After 24h, HF
increased the cardiomyocyte size (167.4± 13.1% vs. control;
Figure S1a, left), and the mRNA expression of brain natriuretic
peptide (BNP) (Figure S1a, right). HG also triggered
cardiomyocyte hypertrophy (183.0±9.4% vs. control; Figure
S1a, left), and the mRNA levels of BNP and cytoskeleton
smooth muscle α-actin (α-SMA) (Figure S1a, right). By other
hand, only HF induced cell death in cardiomyocytes
(145.2±7.8% vs. control. Figure S1b, left) and cardiac
fibroblasts (136.9±4.3% vs. control. Figure S1b, right).
Moreover, HF increased caspase-3 expression and the release
of glucose 6-phosphate dehydrogenase (G6PD), a marker of
necrosis (Figure S1c). Interestingly, GLP-1 pre-treatment
mitigated HF-/HG-induced hypertrophy (97.2±7.5% and
94.3±6.9% vs. HF and HG, respectively) and HF-induced
cardiomyocyte and cardiac fibroblast death (123.6±8.3% and
115.2±6.3% vs. control), and decreased the related pro-
hypertrophic and apoptotic/necrotic markers (Figure S1a, c).
Insulinotropic inactive GLP-1(9-36) exhibited similar
cardioprotective effects than GLP-1
GLP-1 cannot be produced by cardiac cells [26, 27].
However, in cultured cardiomyocytes, exogenous GLP-1 might
be converted to GLP-1(9-36) by the DPP-IV activity [9, 27].
Then, we assayed whether the anti-apoptotic/necrotic, -
hypertrophic and -fibrotic effects of GLP-1 may be a
consequence of GLP-1(9-36) actions. In a similar manner to
GLP-1, GLP-1(9-36) reduced the expression of caspase-3,
G6PD (Figure S1c), BNP/α-SMA (Figure S1a) and fibronectin
(Figure 5a, 3rd and 5th lanes) in HF- and/or HG-stimulated
cardiomyocytes. Moreover, the anti-fibrotic effect of GLP-1 was
reversed by sitagliptin pre-treatment, suggesting a direct role of
GLP-1(9-36) (Figure 5b, 4th lanes). As expected, sitagliptin
alone did not affect the pro-fibrotic proprieties of HL-1 after
both stimuli (not shown).
In addition, although fibroblasts did not express GLP-1R (our
data and [8]), we tested whether they could respond to GLP-1
isoforms by different receptors, as previously suggested [27].
HF and HG also triggered fibronectin expression in cardiac
fibroblasts, and both GLP-1 and GLP-1(9-36) reduced also
these levels (Figure 5c, 3rd and 5th lanes). A similar result was
seen in TFB cells and H9c2 cardiomyocytes, which also lack
GLP-1R (not shown).
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Figure 4.  GLP-1 reduced pro-fibrotic molecules in HF- or HG-stimulated cardiomyocytes.  (a) GLP1R expression in the GK
model (left) (n=5, each group), and HL-1 stimulated cardiomyocytes (right). A representative QPCR-amplification plot of each rat or
stimulated cell is also showed. (b) Intracellular (by WB and IF) and (c) secreted levels of fibronectin (FN) in GLP-1-pre-treated
cardiomyocytes exposed to HF (0.25 mM) or HG (33 mM). (d) Pro-fibrotic expression (TGFß1 and CTGF) in stimulated
cardiomyocytes. *p<0.05 and **p<0.01 vs. control. †p<0.05 and ††p<0.01 vs. HF or HG.
doi: 10.1371/journal.pone.0078330.g004
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Figure 5.  Anti-fibrotic effects of GLP-1 and GLP-1(9-36) on HF- or HG-incubated cardiomyocytes and cardiac
fibroblasts.  Implication of PPARδ. (a) Fibronectin levels in GLP-1 and GLP-1(9-36) pre-treated cardiomyocytes exposed to HF
(left) or HG (right). Some cells were also incubated with a PPARδ antagonist (G5797). (b) Pre-treatment of sitagliptin in GLP-1 +/-
HF-/HG-stimulated cardiomyocytes. (c) Fibronectin expression was also examined in cardiac fibroblast. *p<0.05 and **p<0.01 vs.
control. †p<0.05 and ††p<0.01 vs. HF or HG. §p<0.05 vs. HF+GLP-1 or HG+GLP-1.
doi: 10.1371/journal.pone.0078330.g005
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PPARδ mediated the anti-fibrotic actions of GLP-1
stimulation
A proposed GLP-1 downstream mediator could be the
peroxisome proliferator activating receptor-δ (PPARδ) [28, 29].
In this regard, a significant decrease of PPARδ levels was
noted in the GK myocardium, and this effect was normalized by
sitagliptin (Figure 6a), but not metformin (Figure 6b). Since
PPARδ had demonstrated anti-fibrotic proprieties in the heart
[12, 13], but its role on the diabetic scenario was unknown, we
first tested whether PPARδ activation may affect fibronectin up-
regulation induced by HF or HG. Intriguingly, a PPARδ agonist
(GW0742) pre-treatment attenuated fibronectin levels only in
HG-stimulated cardiomyocytes (Figure 6c, 6th lane). Thus, in
concordance, the anti-fibrotic effect of GLP-1, but not
GLP-1(9-36), was significantly reverted by a specific PPARδ
antagonist (G5797) in HF- or HG-stimulated cardiomyocytes
(Figure 5a, 4th lanes). Similar data were also observed in
cardiac fibroblasts (Figure 5c, 4th lanes).
Direct protective effects of metformin on cardiac cells
Since both sitagliptin and metformin similarly reduced fibrosis
in the GK heart, and GLP-1 triggered anti-fibrotic actions on
cultured cardiomyocytes and cardiac fibroblasts, we tested
whether metformin may also induce direct anti-fibrotic influence
on cardiac cells. Indeed, we observed a reduction of fibronectin
up-regulation in HG-stimulated cardiomyocytes (not shown)
and TFB fibroblasts (Figure 6d) pre-treated with metformin. In
addition, a known metformin-mediator playing key roles in DCM
[30], AMP-activated protein kinase (AMPK), was also activated
(phosphorylated) in HG+metformin cells. However, metformin
did not diminish fibronectin levels after HF, nor increased
phosphorylated-AMPK despite AMPK was over-expressed
(Figure 6d). In this regard, AMPK could be used for
deacetylation processes in mitochondria biogenesis [30]. Of
note, metformin also reduced the expression of caspase-3, and
the release of G6PD, but not BNP/α-SMA mRNA
overexpression, in HF- and/or HG-stimulated cells (Figure S1
a, c).
Discussion
T2DM per se can damage the heart. Non-hypertensive non-
obese GK rats exhibited an accumulation of ECM in the
myocardium, and up-regulation of pro-fibrotic TGFß1, CTGF
and main ECM components such as type-I collagen and
fibronectin. These data are in consonance with previous results
in type-I diabetic rodents [31, 32]. Importantly, cardiac fibrosis
may be induced by direct stimulation of released cytokines
and/or indirectly by a mechanism of replacing died cells, thus
preserving the structural integrity of the myocardium. However,
fibrosis may increase hypertrophy and cardiac dysfunction [2,
4, 33]. In this regard, GK showed cardiac and myocellular
hypertrophy that along with data suggest diastolic dysfunction.
Unexpectedly, EF was elevated in GK rats. This could be a
consequence of the reduction of cavity volume and near-
complete emptying of the ventricle in order to maintain cardiac
output, as occurs in hypertrophied hearts [34]. In this sense,
human and experimental diabetic-associated heart failure has
been also described without a reduction of EF [35, 36].
To date, there is not a specific treatment for DCM-associated
fibrosis. DPP-IV inhibitors, as sitagliptin, suppress the DPP-IV
activity and consequently, prolong GLP-1 half-life. GLP-1
accounts for at least 50-70% of postprandial insulin secretion,
improving the glycemic control by a glucose-dependent
mechanism [5]. In our data, sitagliptin reduced hyperglycemia
and glucose intolerance. Moreover, we described a lipid-
lowering influence. Other DPP-IV inhibitors have also showed
hypolipidemic effects on T2DM patients [37, 38]. The
mechanisms for this lipidemic control may be related to the
GLP-1 effect on lipid absorption [39], metabolism [40] and/or
PPARs activation (see later). More interestingly, sitagliptin
attenuated cardiac apoptosis/necrosis, hypertrophy and fibrosis
in experimental T2DM. These effects may respond to an
increased insulin response by plasma GLP-1 stabilization. In
fact, in these rats metformin induced similar anti-apoptotic/
necrotic, -hypertrophic and -fibrotic actions, and improved
cardiac function. However, other sitagliptin-associated
cardioprotective actions have been reported in non-diabetic
injuries. Sitagliptin reduced the infarct size in mice with
ischemia-reperfusion [41], and diminished post-ischemic
stunning in patients with coronary artery disease and preserved
LV function [42]. Also, a GLP-1-analogue treatment improved
cardiac function in non-diabetic infarcted patients. Thus,
besides its insulin-dependent glycemic and lipidemic control,
sitagliptin might play salutary roles by direct actions of GLP-1
on cardiac cells [6]. In this regard, although GLP-1 is
expressed in brain, pancreas or intestine, but not heart [26], the
presence of GLP-1R have been demonstrated in
cardiomyocytes [8], and GLP-1R knockout mice displayed
impaired LV contractibility and diastolic function [45]. We have
confirmed GLP-1R expression in rat hearts and HL-1
cardiomyocytes, and also, we have detected alleviation of the
pro-apoptotic/necrotic, hypertrophic and fibrotic expression in
GLP-1 pre-treated cardiomyocytes exposed to HF and/or HG.
Previous data indicated also anti-apoptotic actions of GLP-1 in
HL-1 cells [18]. However, these effects may respond also to the
action of its metabolite GLP-1(9-36). In fact, we found similar
effects on HF- and/or HG-stimulated cardiac cells for
GLP-1(9-36), and sitagliptin reversed at least the anti-fibrotic
action of GLP-1. GLP-1(9-36) may also promote
cardioprotection in T2DM. In this regard, GLP-1(9-36) exerted
anti-oxidant effects on cardiac and vascular cells [28, 46].
Thus, since metformin and GLP-1(9-36) induce similar anti-
apoptotic/necrotic, -hypertrophic and -fibrotic actions than
GLP-1, the cardioproptective effects observed after sitagliptin
administration should be firstly explained by its insulinotropic
proprieties. Moreover, we have also described direct anti-
apoptotic/necrotic and anti-fibrotic effects of metformin on HF-
or HG-stimulated cardiac cells, likely involving AMPK
activation. Similar results were found in H2O2- and TGFß-
incubated cardiomyocytes and fibroblasts, respectively [47]
[48]. However, these in vitro approaches may not accurately
reproduce in vivo GLP-1 secretion and DPP-IV inhibition (or
metformin cardiac bioavailability), and the large population of
cardiac non-myocytes/fibroblasts that express pro-fibrotic
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Figure 6.  PPARδ and fibronectin expression in the heart.  Representative blots of PPARδ levels in (a) wistar, GK, GK-sitagliptin
and (b) GK-metformin rats (n=10, each group). (c) Fibronectin and PPARδ expression in HF-/HG-incubated cardiomyocytes pre-
treated with a PPARδ agonist (GW0742) or antagonist (G5797). *p<0.05 vs. control. †p<0.05 and ††p<0.01 vs. GK or HG. §§p<0.01
vs. HF or HG. (d) Reduction of fibronectin in metformin-treated fibroblasts. Fibronectin, AMPK-phosphorylated and AMPK
levels in HF-/HG-incubated TFB +/- metformin. *p<0.05 vs. control. †p<0.05 vs. HF or HG. §p<0.05 vs. HG.
doi: 10.1371/journal.pone.0078330.g006
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factors could differentially respond to GLP-1 isoforms (or
metformin). Further investigations studying the potential
interactions between GLP-1R and metformin-linked mediators
(i.e. AMPK) could be of high interest (Figure 7). In this sense,
GLP-1 may also directly counteract the pro-oxidative,
inflammatory and apoptotic activities induced by angiotensin-II
[43,44].
Moreover, the cellular mechanisms activated by GLP-1
isoforms are not elucidated. GLP-1 and GLP-1(9-36) can signal
by GLP-1R or different receptors [28, 46]. Indeed, we observed
that although cardiac fibroblasts did not express GLP-1R, both
GLP-1 and GLP-1(9-36) reduced the pro-fibrotic expression
after HF or HG. Downstream, cardiac cAMP-dependent RISK
kinases have been involve in the GLP-1R signalling to activate
different transcription factors, such as PPARδ [49-52]. PPARδ,
a highly expressed nuclear receptor in cardiac cells, promotes
healthy activities in the diabetic heart by up-regulation of FFA-
oxidation enzymes [53]. Additionally, PPARδmay also control
the pro-fibrotic expression [54]. We observed a lessening of
HG-induced fibronectin expression after PPARδ-agonist
administration. In HF-stimulated cells a PPARδ-agonist did not
change fibronectin levels possibly because PPARδ can be also
a mediator of FFA signaling. Wagner et al. described a
reduction of myocardial collagen in PPARδ-agonist treated
mice [52]. In addition, we noted that sitagliptin, but not
metformin, returned PPARδ levels in GK hearts. Also, in
HF-/HG-stimulated cardiomyocytes, GLP-1, but not
GLP-1(9-36), reduced pro-fibrotic factors in a PPARδ-
dependent way. In this regard, a GLP-1-analogue increased
myocardial PPARδ and reduced apoptosis in infarcted mice
[29]. Altogether, at least for the anti-fibrotic effect, GLP-1 could
show more affinity for GLP-1R than GLP-1(9-36), and this
receptor may be linked to PPARδ activation (Figure 7).
However, further experiments are required to establish the
precise assembly of this phenomenon.
Study limitations
Another incretin, termed glucose-dependent insulinotropic
polypeptide (GIP), will be increased after DPP-IV inhibition.
However, GIP is much less active and its receptor is profoundly
decreased under hyperglycemia [55]. Also, we cannot exclude
that other potential DPP-IV targets, such as stromal cell-
derived factor-1 chemokine [5] [28], might affect some
cardiovascular responses.
Conclusions
In chronic experimental DCM, the apoptotic and fibrotic
responses may promote myocardial hypertrophy and
remodelling. However, DPP-IV inhibitors as sitagliptin, through
plasma GLP-1 stabilization and insulin control of
Figure 7.  Hypothesised anti-fibrotic mechanisms activated in sitagliptin- or metformin-treated GK hearts.  In T2DM cardiac
cells, two major components such as HF and HG can trigger pro-fibrotic molecules (i.e. fibronectin) through activation of specific
mediators [TGFß1, CTGF, ROS and transcription factors (TF)]. This response may be primarily attenuated by the GLP-1- or
metformin-induced insulinotropic effect. However, a direct anti-fibrotic action of GLP-1GLP-1RPPARδ or metforminAMPK may also
occur. In addition, the GLP-1 truncated isoform [GLP-1(9-36)] may also conserve anti-fibrotic properties by a GLP-1R-dependent or
independent way. R; unknown receptor.
doi: 10.1371/journal.pone.0078330.g007
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hyperglycemia/lipidemia, reduced the cardiac pro-apoptotic/
necrotic, hypertrophic and fibrotic expression in a similar way to
metformin. However, in the presence of high concentrations of
palmitate or glucose, cultured cardiac cells demonstrated a
direct effect of GLP-1PPARδ, GLP-1(9-36) and metformin on
related factors through GLP-1R or distinct receptors.
Furthermore, the cardioprotective actions of GLP-1(9-36)
suggests additional benefits of GLP-1 analogues, which do not
interfere with the physiological GLP-1 degradation, over the
ones from DPP-IV inhibitors in diabetic and, interestingly, non-
diabetic cardiomyopathies.
Supporting Information
Figure S1.  GLP-1 isoforms alleviated the pro-hypertrophic
and lethal responses after HF- and/or HG-stimulation in
cardiac cells. (a, left) HF-/HG-incubated cardiomyocytes were
pre-treated with GLP-1, and F-actin (red) was detected by IF
for cell-size quantification. (a, right) Some cells were used for
BNP and α-SMA mRNA detection. (b) Dying cardiomyocytes
(left) or cardiac fibroblasts (right) were observed under
microscopy after HF/HG-stimulation and GLP-1 pre-treatment.
(c) Caspase-3 expression and the release of G6PD to the
cultured media was measured in stimulated cardiomyocytes.
*p<0.05 and **p<0.01 vs. control. †p<0.05 and ††p<0.01 vs.
HF or HG.
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